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RESULTS: The two methods of measuring BNP (Biosite and Bayer) gave nearly identical
results. One hour following a bolus dose of Natrecor, the average concentrations of BNP
increased about three fold (<0.001). For example, in patients who received the 48 hour
infusion, the average baseline, 1 hour, 48 hour and 12 hour post infusion concentrations
of BNP (Biosite assay) were 1100, 3700, 1900 and 600 pg/mL respectively. The 12 hour
post infusion concentration of BNP was significantly lower (<0.05) than baseline for this
group. In contrast to the BNP results, proBNP concentrations did not increase following
Natrecor administration. For example, in the 48 hour infusion group, the average base-
line, 1 hour, 48 hour and 12 hour post infusion concentrations of proBNP were 9600,
9100, 4400 and 4400 pg/mL respectively. At the end of the infusion and 12 hours after
the infusion, the concentrations of proBNP were significantly (<0.001) lower than base-
line for this group. The proBNP results were not as easily interpreted for the groups that
received infusions < 48 hours.
CONCLUSION: Following the bolus dose, average BNP concentrations trended down
during the infusion, suggesting both drug clearance and turn-off of endogenous synthe-
sis. The decrease in proBNP likely reflects turn-off of endogenous synthesis. Thus both
BNP (endogenous and drug) and proBNP (endogenous secretion) levels can be used to
monitor the concentrations of these peptides in patients administered Natrecor.
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BACKGROUND: Although echocardiography is the gold standard test for the suspected
Left Ventricular dysfunction (LVD),the cost and availability, limits its use as a routine
screening tool. Determining an appropriate BNP level below that would preclude the
need for echocardiography would be valuable. We hypothesized that a fixed plasma BNP
level of 20pg/ml and simple clinical parameters would be an effective pre-echocardio-
graphic screening tool for LV dysfunction. METHODS: 202 VA subjects with symptoms
suggestive of heart disease (m:f 193:9, mean-age 65) were screened prior to echocar-
diography. Patients with known cardiac dysfunction were excluded. RESULTS: BNP lev-
els of 20pg/ml and above were 79% sensitive and 44% specific in screening for any
abnormality of ventricular function.The negative predictive value was 69%.When broken
down into categories of dysfunction, the cut point of 20pg/ml had a better negative pre-
dictive value for those with systolic dysfunction (96%), or systolic plus diastolic dysfunc-
tion (100%) if patients with diastolic dysfunction were excluded. The majority of patients
with falsely low BNP levels (<20pg/ml with positive echo findings) had mild diastolic dys-
function,with 3 patients exhibiting mild systolic dysfunction. CONCLUSION: BNP may be
useful screening tool for LVD in patients with history suggestive of heart disease and may
assist in forming a pre-test probability which could greatly assist in appropriateness of
patient referral and in optimization of drug therapy.
1049-114 Increasing Atrial Natriuretic Peptide Over Time 
Independently Predicts Higher Short-Term Mortality and 
Morbidity in Heart Failure
Raymond T. Yan, Rizwan Afzal, Robert S. McKelvie, McMaster University, Hamilton, ON, 
Canada
Background: Baseline measurements of various neurohormones (NH) have been
reported as useful prognostic markers in heart failure (HF). However, the prognostic val-
ues of changes in these different NH over time have not been examined.
Methods: We evaluated 768 subjects with symptomatic HF and left ventricular ejection
fraction <0.40 randomized to various combinations of candesartan, enalapril and meto-
prolol in RESOLVD. Changes (∆) (week 17 - baseline) in each measured NH were com-
pared between subjects with and without subsequent (week 17 to week 43) death or HF
hospitalization, and their independent prognostic significance were determined by Cox
regression analysis.
Results: All NH were abnormally elevated at baseline. Subjects who subsequently died
or required hospitalization for HF had significantly larger increases in atrial natriuretic
peptide (ANP) and smaller decreases in norepinephrine (NE). In Cox regression analy-
sis, every 2-fold increase in ANP over time independently predicted an increased risk of
subsequent death or HF hospitalization (Hazard ratio 1.53, 95% CI 0.93 to 3.63, p=0.07).
Changes in other NH conferred no incremental prognostic value. 
Conclusion: Increasing ANP over time independently predicted a trend towards higher 
short-term mortality and morbidity in chronic HF patients on neurohormonal therapies. 
Serial measurements for changes in ANP may help to identify higher risk HF patients and 
should be evaluated in further studies.
1049-115 The Value of B-Type Natriuretic Peptide and Cardiac 
Troponin I as Predictors of Sudden Death in Patients 
With Advanced Heart Failure
Mark M. Lensky, Tamara B. Horwich, Gregg C. Fonarow, University of California at Los 
Angeles Medical Center, Los Angeles, CA
Objectives: The study aimed to evaluate the potential role of BNP and cardiac troponin I
(TnI) as predictors of sudden death (SD) in patients with advanced heart failure (HF).
Background: Earlier studies have reported that BNP and TnI are predictive of mortality
in HF patients: their role in predicting SD in HF has not been well studied.
Methods: We analyzed 757 advanced HF patients followed in a comprehensive HF man-
agement program of which 303 had baseline BNP and 403 had TnI determined. The
patients were grouped into those with undetectable TnI < 0.04 ng/mL (n = 187) and
detectable TnI > 0.04 (n = 216) as well as those with BNP < 950 pg/mL (n= 226) and
BNP > 950 (n =77). The BNP cut point was selected based on ROC curves for SD.
Results: Of 110 deaths during 2 years of follow-up 42 (38%) were classified as SD.
Detectable TnI (OR 2.81, 95% CI 1.70-4.64) and BNP > 950 (OR 8.76, 95% CI 4.65-
19.50) predicated significantly increased risk of all-cause mortality. While BNP > 950 was
highly predictive of SD risk (OR 4.75, 95% CI 1.32-17.15), detectable TnI was only asso-
ciated with a non-significant trend (OR 1.72, 95% CI 0.78-3.79). On multivariate analysis,
BNP < 950 was a strong predictor of SD free survival; non-detectable TnI was not.
Conclusions: In a large cohort of patients with advanced HF of multiple etiologies, ele-
vated BNP, but not detectable TnI, is highly predictive of increased risk for SD. Prospec-
tive studies are needed to test if BNP can be used to guide prophylactic Implantable
Cardioverter Defibrillator device placement in HF.
1049-116 B-Type Natriuretic Peptide Does Not Correlate With 
Volume Overload or Left Ventricular Dysfunction in 
Patients With Multiple Comorbidities
Sukesh C. Burjonroppa, Mary Vooletich, Daniel J. Lenihan, University of Texas, MD 
Anderson Caner Center, Houston, TX
Background: B type Natriuretic peptide (BNP) has been shown to be an important
marker of left ventricular (LV) systolic dysfunction and volume overload (VOL) in patients
with symptomatic heart failure (HF).In addition, the level of BNP elevation in HF has cor-
related with prognosis. However marked elevation of BNP can be noted without VOL.
Thus, we hypothesized that these elevated BNP levels may reflect non-specific eleva-
tions due to co-morbid diseases rather than due to VOL alone.
Methods: Over a 6-month period, all patients admitted with BNP levels greater than
1000 pg/ml were identified. The demographics, co-morbidities including the presence of
sepsis, any clinical evidence of VOL (S3 gallop, bilateral basilar crackles, bilateral pedal
edema, jugular venous distension, pulmonary edema) and measurement of LV ejection
fraction (LVEF) within 48 hours of the BNP data were defined.
Comparison of BNP cut off of 20pg/ml vs Echocardiography as a screening tool in 
Cardiac Failure
Sensitivity Specificity Positive 
Predictive 
Value
Negative 
Predictive 
Value
Accuracy
All Unknown 
LVD
79%(69-86) 44%(35-54) 57%(48-65 69%(56-79 61%
Only Systolic 80%(50-98) 36%(30-44) 10%(6-16) 96%(87-99) 40%
Only Diastolic 75%(63-84) 38%(30-47) 40%(32-49) 73%(61-83) 51%
Systolic & 
Diastolic
100%(70-105) 35%(29-42) 8%(5-14) 100%(94-100) 39%
Subjects without 
Death or HF 
hospitalization
(Mean ± SD)
(N=598)
Subjects with 
Death or HF 
hospitalization
(Mean ± SD)
(N=87)
P–value
t-test
∆ ANP (pmol/ml) -21.5 ± 628.2 +293.7 ± 648.3 0.006
∆ NE (pg/ml) -48.5 ± 242.9 - 22.3 ± 232.5 0.04
∆ Brain natriuretic peptide (pmol/ml) - 5.3 ± 35.8 + 1.2 ± 52.0 0.15
∆ Endothelin (pg/ml) - 0.63 ± 3.63 - 0.36 ± 2.25 0.36
∆ Angiotensin (pg/ml) + 5.8 ± 30.2 + 13.5 ± 34.8 0.59
∆ Aldosterone (pg/ml) - 9.5 ± 102.2 - 14.7 ± 102.5 0.92
∆ Epinephrine (pg/ml) - 24.1 ± 92.4 - 26.7 ± 56.5 0.80
